Fred Hutchinson Cancer Research Center

University of Washington Cancer Consortium / SCCA

Seattle, WA

Sorting 24 by

Accepting patients

Optimized Cord Blood Transplant

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics
  • Cord Blood
  • Phase 2

Accepting patients

RALLY-MF

RALLY-MF: A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and AnemiaA Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
  • Monoclonal Antibody
  • Hemojuvelin (HJV)
  • Randomization
  • Monotherapy
  • Phase 1/2
  • Has results

Accepting patients

BH-30236

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
  • CLK Inhibitor
  • Phase 1

Accepting patients

Ruxolitinib During Stem Cell Transplant

Peri-Hematopoietic Cell Transplantation Ruxolitinib in Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
  • JAK2 Inhibitor
  • Allogeneic Stem Cell Transplant
  • JAK1 Inhibitor
  • Phase 2

Accepting patients

ACCELERATE

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  • Allogeneic Stem Cell Transplant
  • Post-Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Orca-Q

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
  • Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

Naïve T Cell Depletion

Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
  • Allogeneic Stem Cell Transplant
  • Pre-Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

RAFA

A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

TRX-103

Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
  • T Cell (Allogeneic)
  • Post-Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

Graft Versus Host Disease-Reduction Strategies

A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
  • Allogeneic Stem Cell Transplant
  • Phase 2